Vanguard Capital Management
CRL icon

Vanguard Capital Management’s Charles River Laboratories CRL Stock Holding History

Vanguard Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$923M Sell
3,127,823
-21,465
-0.7% -$5.66M 0.02% 496
2026
Q2 		$714M Sell
3,149,288
-52,916
-2% -$9.42M 0.02% 592
2026
Q1 		$552M Buy
+3,202,204
New +$594M 0.01% 636

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Ariel Investments
Ariel Investments Chicago, Illinois $9.6B AUM 22.21% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $25.4B AUM 35.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Vanguard Capital Management's CRL Position: Q3 2026 in Review

Vanguard Capital Management reduced its Charles River Laboratories (CRL) stake by 0.68% in Q3 2026, selling an estimated $5.66M and leaving 3,127,823 shares worth $923M. The position accounts for 0.02% of the portfolio, ranked #496.

Vanguard Capital Management first reported a position in CRL in Q1 2026 and has held it in 3 quarters since. 515 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Vanguard Capital Management held 3,127,823 shares of Charles River Laboratories worth $923M as of Q3 2026.
  • Vanguard Capital Management sold 21,465 Charles River Laboratories shares in Q3 2026, an estimated $5.66M.
  • Charles River Laboratories made up 0.02% of Vanguard Capital Management's portfolio in Q3 2026, its #496 holding.
  • Vanguard Capital Management first reported a position in Charles River Laboratories in Q1 2026 and has held it in 3 quarters since.
  • 515 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.